Browse the corpus

A papulonodular rash with transepidermal elimination of dermal components characterizes perforating dermatoses. Traditionally, four classic forms of primary perforating dermatosis have been described: Kyrle disease, reactive perforating collagenosis, elastosis perforans serpiginosum, and perforating folliculitis. The secondary form of this condition is known as acquired perforating dermatosis. This term describes all perforating dermatoses affecting adults with diabetes mellitus, chronic renal failure, and, rarely, other systemic diseases. This activity reviews the evaluation and management of patients with acquired perforating dermatosis and highlights the importance of the interprofessional team in caring for patients with this condition. Objectives: Identify the diagnostic criteria for acquired perforating dermatosis. Evaluate the histopathological features of acquired perforating dermatosis. Assess the common complications of acquired perforating dermatosis. Communicate how the interprofessional team can work collaboratively to prevent the potentially profound complications of acquired perforating dermatosis by applying knowledge about this disease's presentation, evaluation, and management. Access free multiple choice questions on this topic.

Perforating dermatoses are a heterogeneous group characterized by a papulonodular rash with transepidermal elimination of dermal components. Traditionally, 4 classical forms of primary perforating dermatosis have been described, where the transepidermal elimination mechanism represents the hallmark of the disease: Kyrle disease, reactive perforating collagenosis, elastosis perforans serpiginosum, and perforating folliculitis.[1] Elastosis perforans serpiginosum begins in childhood and characteristically presents with eliminating elastic fibers. Reactive perforating collagenosis also occurs during childhood with the expulsion of collagen fibers. In perforating folliculitis, the content of the follicle, with or without collagen or elastic fibers, gets eliminated. Finally, Kyrle disease presents with transepidermal elimination of abnormal keratin.[2] However, there is some controversy in the literature considering the classification of Kyrle disease. While a few authors consider Kyrle disease to be an acquired form of perforating dermatosis, some define it as a variant of prurigo nodularis, representing the end-stage of excoriated folliculitis.[3] The secondary form of this condition is acquired perforating dermatosis (APD). See Image. Acquired Perforating Dermatosis. The term was proposed by Rapini in 1989 to designate all the perforating dermatoses affecting adults with diabetes mellitus, chronic renal failure (CRF), and rarely, other systemic diseases, regardless of the eliminated dermal material.[3] Commonly, patients with APD present with umbilicated papules and plaques with predilection sites that include the trunk and extremities.[4] Although the pathogenesis of APD remains unclarified, some authors suggested that trauma and microvasculopathy may be the triggers of transepidermal elimination and degeneration of the collagen fibers.[5]

Both sexes are equally affected. Acquired perforating dermatosis usually occurs during the fifth decade of life.[6] The exact prevalence and incidence of acquired perforating dermatosis are unknown. A retrospective study of patients diagnosed with APD between 2002 and 2014 included 33 patients. This estimated incidence was 2.53 cases per 100000 inhabitants per year. While this reported incidence is very low, the authors believed that actual APD occurs more commonly. The disease could potentially be underdiagnosed or misdiagnosed as simple excoriations.[4][7] According to published studies, acquired reactive perforating collagenosis was found to be the most common form, while Kyrle disease and perforating folliculitis were the least frequent types of APD.[6] Previous reports have documented the association of acquired perforating dermatosis with various systemic diseases, especially CRF, diabetes mellitus, or both.[5][8][9] suspected that dialysis treatment plays a key factor in the development of APD in diabetic patients.[9] Other associated disorders rarely reported include hepatic dysfunction, HIV infection, hypothyroidism, hyperparathyroidism, atopic dermatitis, and cancers such as liver carcinoma, pancreas adenocarcinoma, Hodgkin’s disease, and myelodysplastic syndrome.[3][6][9][10]

Although the pathogenesis of acquired perforating dermatosis is unclear, many hypotheses exist. Patients with APD often exhibit the Koebner phenomenon, where skin lesions develop at the sites of trauma and are exacerbated by scratching.[5][11] Another postulated theory is that self-induced trauma to the skin damages the epidermis or dermal collagen, which eventually causes the onset of APD.[3][9][11] Moreover, leukocyte infiltration observed in skin lesions secretes interleukin-1, which is a stimulator of the synthesis of metalloproteinases, resulting in degrading the components of the extracellular matrix.[10] Finally, according to some authors, the interplay of microtrauma, altered wound-healing capacities, and tissue hypoxia caused by diabetes and also the microangiopathy and oxidative stress associated with CRF are considered to be the triggers of acquired perforating dermatosis.[11][12]

Skin biopsy is mandatory for the diagnosis of acquired perforating dermatosis. However, the pathological features of this condition are not uniform. They may resemble any of the 4 classic perforating dermatoses, including reactive perforating collagenosis, elastosis perforans serpiginosum, perforating folliculitis, or Kyrle disease. Frequently, more than 1 pattern is observed in the same patient.[9][11] Therefore, many authors prefer to lump all these diagnoses into 1 umbrella term of acquired perforating dermatosis. The histology of APD classically shows epidermal invagination, often involving a dilated hair follicle with a keratotic plug consisting of collagen, keratin, or elastic fibers. The principal diagnosis feature is a central keratotic core overlying a focus of epidermal perforation.[11]

Acquired perforating dermatosis may manifest with several polymorphous skin lesions, such as hyperkeratotic, often umbilicated, millimetric, or larger papules or nodules. Erythematous or non-erythematous lesions can also be found in follicular or non-follicular regions, depending on the APD type.[6] Since pruritus is very frequent, excoriations and crusts are common presenting signs. New skin lesions can emerge due to Koebnerization.[5][6][10] Most skin lesions develop on the extensor surfaces of the lower extremities, but APD can also be present on the trunk, scalp, or any area that the patient may scratch or rub due to pruritis.[4][11] Faver et al proposed diagnostic criteria of acquired reactive perforating collagenosis as follows: onset of the disease after the age of 18 years, the presence of umbilicated nodules or papules with a central adherent plug, and elimination of necrotic collagen tissue within an epithelium-lined crater.[8]

Diagnosis of acquired perforating dermatosis relies on the patient’s history, the clinical presentation of the lesions, and especially histopathology with recognition of classic histological features. Dermatoscopic findings during APD show bright white clouds and structureless grey areas, which may be useful in distinguishing APD from prurigo nodularis.[4] However, multiple biopsies are still the recommended procedure before establishing a definitive diagnosis. Estimating blood glucose levels and hepatic and renal function is highly recommended to identify the underlying disease.

No controlled studies or guidelines exist for the treatment of acquired perforating dermatosis. All proposed treatments have their basis in previously published case reports or small series. The goal of treatment should include the management of the underlying disease and the relief of pruritus.[6][13] First-line treatment strategies include systemic or topical corticosteroids, retinoids, and keratolytic agents such as urea or salicylic acid. Emollients and oral antihistamines are frequently prescribed to relieve pruritus.[13] Nevertheless, other treatment options are often needed, and there are reports of successful outcomes with tetracyclines, retinoids, phototherapy, and allopurinol.[6][14] Tetracyclines have anti-inflammatory properties and are potent inhibitors of matrix metalloproteinases.[15] Retinoids are prescribed to stabilize keratinocytes and protect collagen from focal damage and epidermal necrolysis.[6] Allopurinol may disrupt collagen glycation by inhibiting xanthine oxidase through its antioxidant effects.[6][14] Phototherapy in NB-UVB and PUVA has improved the management of pruritus and skin lesions.[14] Finally, combination treatment, rather than monotherapy, may be more successful.

Differential diagnosis for acquired performing dermatosis includes: Folliculitis Prurigo nodularis Arthropod bites Porokeratosis Scabies Keratosis pilaris Excoriated dermal diseases (such as lichen planus and granuloma annulare) Multiple keratoacanthomata Hyperkeratosis lenticularis perstans Perforating pseudoxanthoma elasticum [1][6][10]

Due to the multifactorial nature of the disease, disease-specific prevention strategies are difficult to identify. Patients, however, may experience significant quality of life and psychological impacts from the disease. Patient reassurance and education on compliance are needed to ensure adequate outcomes.

Acquired perforating dermatosis often demonstrates severe pruritus and can have a significant impact on the patient’s quality of life. Therefore, physicians, nurse practitioners, and physician assistants should be aware of this characteristic dermatosis in patients with diabetes or CRF receiving hemodialysis, given that early diagnosis and treatment can prevent the disease's progression, which improves prognosis. Also, more studies on the clinical and histological features of APD are still needed to enlighten the etiopathogenesis of this condition, as the current literature remains poor and centers on case reports or small case series. The optimal approach to addressing this rare condition involves an interprofessional team consisting of physicians, mid-level providers, nurses (particularly with specialty training in dermatological care), and pharmacists; this approach to caring for these patients yields the best results.